SLC2A1 and glioblastoma: The administration of OMX in mice with individual orthotopic glioblastoma tumors resulted in a reduction of over 50% in the hypoxic tumor area, as evidenced by immunostaining with glucose transporter 1 (Glut1) and HIF-1α markers [9].